The borderland down under

The symptom of hypersomnolence significantly impairs quality of life. Central disorders of hypersomnolence, including narcolepsy types one and two (NT2) and idiopathic hypersomnolence (IH), are treated with stimulant medications that are often incompletely effective and cause burdensome adverse effects. Improving management of these conditions is a key challenge for the field. The lived experience of people with IH is thus an important, yet often overlooked, factor, despite calls for greater appreciation of IH symptoms not directly related to sleepiness, the content of patient–clinician interactions, comorbidities, and impacts on daily life.